Rezolute(US:RZLT) Globenewswire·2025-12-30 17:45Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rezolute, Inc. and its officers or directors following disappointing clinical trial results that led to a significant drop in the company's stock price [1][3]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company on NASDAQ under the ticker RZLT [1]. - The company recently announced topline results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [3]. Group 2: Clinical Trial Results - The Phase 3 study did not meet its primary endpoint, which was to assess the change in average weekly hypoglycemia events, showing only a 45% reduction in events at the highest dose of ersodetug (10 mg/kg), which was not statistically significant compared to a 40% improvement in the placebo group [3]. - The study also failed to meet its key secondary endpoint, with a 25% reduction in average daily percent time in hypoglycemia at the 10 mg/kg dose, again not statistically significant compared to a 5% increase in the placebo group [3]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial results, Rezolute's stock price fell by $9.44 per share, or 87.2%, closing at $1.77 per share on December 19, 2025 [3].